ask="4.50"
ask_size="1000"
average_daily_volume="54795"
bid="2.61"
bid_size="100"
book_value="1.19"
change="-0.11"
change_from_200_day_moving_average="-1.22"
change_from_50_day_moving_average="-0.36"
change_from_52_week_high="-3.62"
change_From_52_week_low="0.24"
change_in_percent="-3.70%"
close="2.86"
dividend_pay_date="N/A"
dividend_per_share="N/A"
dividend_yield="N/A"
earnings_per_share="-3.90"
ebitda="-15.74M"
eps_estimate_current_year="-3.71"
eps_estimate_next_quarter="0.00"
eps_estimate_next_year="-2.81"
ex_dividend_date="N/A"
float_shares="5652000"
high="2.99"
high_52_weeks="6.47"
last_trade_date="2/8/2017"
last_trade_price="2.86"
last_trade_size="100"
last_trade_time="3:59pm"
low="2.81"
low_52_weeks="2.62"
market_capitalization="18.01M"
moving_average_200_day="4.08"
moving_average_50_day="3.22"
name="MABVAX THERAPEUTICS"
notes="N/A"
one_year_target_price="18.00"
open="2.97"
pe_ratio="N/A"
peg_ratio="-0.02"
percent_change_from_200_day_moving_average="-29.91%"
percent_change_from_50_day_moving_average="-11.23%"
percent_change_from_52_week_high="-55.83%"
percent_change_from_52_week_low="+9.16%"
previous_close="2.97"
price_eps_estimate_current_year="N/A"
price_eps_Estimate_next_year="N/A"
price_per_book="2.49"
price_per_sales="20.65"
revenue="905615.00"
shares_outstanding="6296000"
short_ratio="7.95"
stock_exchange="NCM"
symbol="MBVX"
volume="29881"
weeks_range_52="2.62 - 6.47"
